VPS33A 通过自促进胆管癌中佩米加替尼布耐药性的促进
Mengyu Chen1,2, Man Luo3,2, Bolin Zhang4,2
1Department of Thoracic Oncology, Jiangxi Cancer Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Digestive diseases and sciences
|February 20, 2026
概括
VPS33A介导的自驱动在胆管癌 (CCA) 中的佩米加替尼布耐药性. 向VPS33A和ULK1可以克服耐药性,为CCA患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 佩米加替尼 (pemigatinib) 是第一个FDA批准的针对胆管癌 (CCA) 的向疗法.
- 对佩米加替尼布的获得性耐药性是CCA治疗中的一个重大临床挑战.
- 了解抵抗机制对于开发有效的治疗策略至关重要.
研究的目的:
- 调查VPS33A在中介CCA中Pemigatinib耐药性的作用.
- 探索自与VPS33A驱动的耐药性的关系.
- 确定潜在的治疗点,以克服佩米加替尼布耐药性.
主要方法:
- 已经确立的耐佩米加替尼布的CCA细胞系 (RBE-R,HuCCT1-R).
- 评估细胞活力,增殖和自流量.
- 为了功能验证,利用了VPS33A的淘汰和ULK1的过度表达.
- 通过相关性分析确认了VPS33A和ULK1的相互作用.
主要成果:
- 耐药细胞显示VPS33A表达升高和自依赖的耐药性.
- VPS33A knockdown抑制了自,降低了ULK1水平,并使细胞对佩米加西尼布敏感.
- ULK1过度表达恢复了自,并逆转了VPS33A枯竭引起的药物敏感性.
结论:
- 通过ULK1,VPS33A介导的自会维持CCA中的佩米加替尼抗性.
- VPS33A代表了一个潜在的治疗点,以克服对佩米加替尼布的耐药性.
- 这项研究揭示了CCA治疗策略的新脆弱性.
更多相关视频
08:07Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence
Published on: April 28, 2023
2.1K
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
978
相关概念视频
Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
PI3K/mTOR/AKT Signaling Pathway
5.8K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.8K
The Intrinsic Apoptotic Pathway
8.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.8K
Autophagy
5.9K
Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
5.9K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
